HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Short-term inhibition of fibrinolytic system restores locomotor function after spinal cord injury in mice.

Abstract
Spinal cord injury (SCI) is caused by an initial mechanical insult followed by a series of deleterious events that promote the progressive damage of affected tissues. Fibrinolysis, the process by which plasmin degrades cross-linked fibrin clots, has numerous functions in the central nervous system. However, the roles of the fibrinolytic system in SCI pathophysiology remain unknown. We investigated the roles of fibrinolysis in SCI, and explored therapeutic applications targeting fibrinolysis. Plasminogen-deficient (Plg-/-) mice exhibited significantly improved locomotor function in the early phase of SCI (the first 7 days post injury), with significant inhibition of bleeding and vascular permeability, but failed to demonstrate conclusive functional recovery. Consistent with these findings, the short-term administration of tranexamic acid (TXA) in wild-type mice over the first 3 days post injury significantly improved locomotor function after SCI, whereas prolonged TXA administration did not. Prolonged TXA administration resulted in significantly lower levels of matrix metalloproteinase activities in the spinal cord, suggesting that inhibition of the fibrinolytic system impaired tissue remodeling. Our results indicate that the fibrinolytic system has time-dependent biphasic actions following SCI. The temporally optimised modulation of fibrinolytic activity may thus be a novel therapeutic strategy to improve functional outcomes after SCI.
AuthorsYasuyuki Shiraishi, Atsushi Kimura, Osamu Matsuo, Yoichi Sakata, Katsushi Takeshita, Tsukasa Ohmori
JournalScientific reports (Sci Rep) Vol. 9 Issue 1 Pg. 16024 (11 05 2019) ISSN: 2045-2322 [Electronic] England
PMID31690812 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chemokines
  • Cytokines
  • Tranexamic Acid
  • Plasminogen
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
Topics
  • Acute Disease
  • Animals
  • Chemokines (metabolism)
  • Cytokines (metabolism)
  • Fibrinolysis (drug effects)
  • Locomotion (physiology)
  • Matrix Metalloproteinase 2 (metabolism)
  • Matrix Metalloproteinase 9 (metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Plasminogen (deficiency, genetics)
  • Recovery of Function (drug effects)
  • Spinal Cord (metabolism, pathology)
  • Spinal Cord Injuries (metabolism, pathology)
  • Tranexamic Acid (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: